ALOX15 and endothelial dysfunction: Interestingly, these differences support the hypothesis of a compensatory mechanism since 5-LOX products are rather detrimental to cardiometabolic health via the induction of inflammation [81,82,83,84], vasoconstriction [85], endothelial dysfunction [85] and platelet aggregation [86], while 15-LOX products have resolving action by reducing polymorphonuclear leukocyte (PMN) activation [87] and chemotaxis [31,81], possibly via negative feedback regulation of 5-LOX [88].